The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy (Q34659699)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy |
scientific article |
Statements
1 reference
The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy (English)
1 reference
Cheolwon Suh
1 reference
Gyeong-Won Lee
1 reference
Min-Hee Ryu
1 reference
Jae-Lyun Lee
1 reference
Sukjoong Oh
1 reference
Eunkyoung Kim
1 reference
Jae-Hwan Lee
1 reference
Seung-Bae Kim
1 reference
Sang-We Kim
1 reference
Kyoo-Hyung Lee
1 reference
Woo-Kun Kim
1 reference
Jung-Shin Lee
1 reference
Yoon-Koo Kang
1 reference
1 December 2003
1 reference
1 reference
18
1 reference
6
1 reference
849-854
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference